The Pim kinases themselves mediate resistance to mTOR inhibition in hematologic malignancies and may partly account for the lack of efficacy encountered.35, 67 The converse may also be true, and it may prove necessary to inhibit the PI3K/Akt/mTOR pathway in tandem for durable results. The gene discussed is AKT1; the disease is hematologic disorder.